New RSV shield for babies cuts hospital visits in first year
NCT ID NCT07177508
Summary
This study looked at how a new preventive medicine called nirsevimab affected Respiratory Syncytial Virus (RSV) in young children. Researchers analyzed routine health data from over 2,300 children under 2 years old in the Australian Capital Territory. They compared RSV infection rates and hospital visits before and after the medicine was introduced to see if it reduced the burden of this common childhood illness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRAL (RSV) INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Canberra Hospital
Garran, Australian Capital Territory, 2605, Australia
Conditions
Explore the condition pages connected to this study.